Sat Apr 25 23:57:28 SGT 2015  
    Vaccine, Singapore (SG)

Vaccine, Singapore (SG)


Vaccine, Singapore (SG) @singaporevaccine_com: vaccine jab/shot/injection schedule, to vaccinate against the infection, to immunise against infectious disease, Singapore. Private and confidential service. Definitions, references, and latest news.


Vaccine types available for vaccination / immunisation (uk) / immunization (us) :

Vaccine Against Disease Age D
Dose schedule Price
Live attenuated
MMR vaccine ≥12m 1 $70/=
Measles virus Measles
Mumps virus Mumps
Rubella virus Rubella
Varilrix™ Varicella zoster virus
Varicella Chickenpox 12m-12y 1 $121/=
≥13y 2 6-10w interval
Zostavax™ Herpes zoster Shingles ≥50y 1 $295/=
Stamaril® Yellow fever virus Yellow fever 9m-59y 1 10 yearly $250/=
Inactivated / Whole / Viral & Bacterial
Rabipur® Rabies virus Rabies any 3 d 0, 7, & 21 or 28 $call/=
Ixiaro® Japanese encephalitis virus Japanese encephalitis ≥17y 2 2nd: 28d after 1st $386/=
1 Booster: 12-24m after 2nd
Dukoral® Vibrio cholerae Cholera 2-6y 3 1-6w interval $113/=
1 Booster: 6m after 3rd
≥6y 2 1-6w interval
1 Booster: 2y after 2nd
Inactivated / Fractional / Protein
Intanza™ Influenza virus Influenza 18-59y 1 1 yearly $30/=
Fluarix™ Influenza virus Influenza 6-36m ½ 1 yearly $30/=
>3y 1
Tetavax Clostridium tetani Tetanus adults 3 1-2m interval
3rd @ 6-12m
after 2nd
booster 1 10 yearly
Boostrix® ≥4y 1 <10 yearly $70/=
Corynebacterium diphtheriae Diphtheria
Clostridium tetani Tetanus
Bordetella pertussis Pertussis
Whooping cough
Inactivated / Fractional / Polysaccharide / Pure
Typhim Vi® Salmonella typhi Typhoid fever >5y 1 3 yearly $48/=
Mencevax® ACWY Neisseria meningitidis
types A, C, W-135
and Y
Meningococcal meningitis >2y 1 $80/=
Inactivated / Fractional / Polysaccharide / Conjugate
Menactra® Neisseria meningitidis
types A, C, W-135
and Y
Meningococcal meningitis 2-55y 1 $195/=
Prevenar 13® (SG) /
Prevnar 13® (US)
Streptococcus pneumoniae
types 1, 3, 4, 5,
6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, 23F
Pneumococcal infection 6w-6m 4 1m interval
4th @ 12-15m
7-11m 2 1m interval
12-23m 2 2m interval
2-5y 1
≥50y 1

If the clinic attendance is just for vaccination alone, no additional consultation fees are charged.

Testing for immunity against the following is available:

Virus Antibody Test Price
Varicella zoster virus Varicella Zoster IgG Antibody $44/=
Measles virus Measles IgG Antibody $90/=
Rubella virus Rubella IgG Antibody $24/=
Hepatitis A virus Hepatitis A IgG Antibody $30/=
Hepatitis B virus Hepatitis B surface Antibody $10/=

Other vaccines not stocked


Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Vaccine, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.


Latest News

Africa: Malaria Vaccine Trial Raises Hopes
Fri, 24 Apr 2015 16:01:12 +0100 | AllAfrica News: Health and Medicine
[Global Fund] Geneva -Gavi, the Vaccine Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria welcome the results of a large-scale trial of a malaria vaccine candidate in sub-Saharan Africa. (Source: AllAfrica News: Health and Medicine)

AS03-Adjuvanted H5N1 Influenza Vaccine in ChildrenAS03-Adjuvanted H5N1 Influenza Vaccine in Children
Fri, 24 Apr 2015 15:05:23 +0100 | Medscape Today Headlines
How safe and effective is the AS03-adjuvanted H5N1 influenza vaccine in children? Influenza and Other Respiratory Viruses (Source: Medscape Today Headlines)

Africa: Lions Clubs Mobilise for World Immunization Week
Fri, 24 Apr 2015 14:34:52 +0100 | AllAfrica News: Health and Medicine
[GAVI] Geneva -Advocacy toolkit launched to help Health Ministries spread the word about vaccination against measles and rubella in developing countries (Source: AllAfrica News: Health and Medicine)

Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine.
Fri, 24 Apr 2015 14:30:05 +0100 | Oncotarget
Authors: Wang X, Zhao F, He X, Wang J, Zhang Y, Zhang H, Ni Y, Sun J, Wang X, Dou J

[Editorial] Vaccines: a step change in malaria prevention?
Fri, 24 Apr 2015 12:35:25 +0100 | LANCET
According to WHO's 2014 World Malaria Report there were an estimated 198 million cases of malaria worldwide in 2013, occurring in around half of the world's countries. These infections resulted in some 584 000 deaths, principally associated with Plasmodium falciparum infection, of which 90% occurred in equatorial Africa. Most distressingly, malaria mortality is concentrated in children, with about 453 000 deaths of children aged younger than 5 years in 2013, the vast majority in African countries. (Source: LANCET)

vaccine-prevent-millions-young-children-catching-disease-available-months-trial-results-reduces-number-cases-half.html?ITO=1490&ns_mchannel=rss&ns_campaign=1490 target=_blank rel="nofollow">Malaria vaccine could be available within months after trial results
Fri, 24 Apr 2015 12:16:07 +0100 | the Mail online | Health
The drug, known as RTS,S, has been developed by British firm GlaxoSmithKline over 30 years, and tests show that it could prevent millions of cases of the disease in very young children. (Source: the Mail online | Health)

A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year.
Fri, 24 Apr 2015 11:57:45 +0100 | Biomaterials
In this study, we describe a biodegradable vaccine depot which persists in vivo for at least 4-months, provides synergistic adjuvant effects and also allows dose sparing of both antigen and adjuvant. A single administration results in immediate release of a priming dose of vaccine, by a process of syneresis, which is then followed by release of remaining vaccine which maintains robust antibody levels that last for more than a year. The platform technology comprises two aqueous components; one contains chitosan and hydroxyapatite, in which the vaccine is incorporated, and the other consists of a crosslinking agent, tripolyphosphate (TPP) and chondroitin sulphate. When co-injected into tissue, they spontaneously crosslink forming a firm yet compliant vaccine-containing depot. Whole body ima...

Microencapsulation of tumor lysates and live cell engineering with MIP-3α as an effective vaccine.
Fri, 24 Apr 2015 11:56:37 +0100 | Biomaterials
In this study, we generated an alginate microsphere (named PaLtTcAdMIP3α) that encapsulated tumor lysates, live tumor cells engineering with a recombinant MIP-3α adenovirus and BCG. We used PaLtTcAdMIP3α as a model vaccine to test its antitumor activities. Our results showed that PaLtTcAdMIP3α expressed and excreted MIP-3α, which effectively attracted DCs ex vivo and in vivo. Injection of PaLtTcAdMIP3α into tumor-bearing mice effectively induced both therapeutic and prophylactic antitumor immunities in CT26, Meth A, B16-F10 and H22 models, but without any ensuing increase in adverse effects. Both tumor-specific cellular and humoral immune responses, especially the CD8(+) T cell-dependent cytotoxic T immunity, were found in the mice injected with PaLtTcAdMIP3α. The anti-tumor activ...

World's first malaria vaccine moves closer to use in Africa
Fri, 24 Apr 2015 08:39:07 +0100 | Reuters: Health
LONDON (Reuters) - The world's first malaria vaccine, made by GlaxoSmithKline, could be approved by international regulators for use in Africa from October after final trial data showed it offered partial protection for up to four years. (Source: Reuters: Health)

Scientists announce final trial results of the world’s most advanced malaria vaccine
Fri, 24 Apr 2015 01:13:20 +0100 | ScienceDaily Headlines
The first malaria vaccine candidate (RTS,S/AS01) to reach phase 3 clinical testing is partially effective against clinical disease in young African children up to 4 years after vaccination, according to final trial data. The results suggest that the vaccine could prevent a substantial number of cases of clinical malaria, especially in areas of high transmission. (Source: ScienceDaily Headlines)